Researchers synthesize chimeric peptide that elicits antitumor activity for cancer immunotherapy

Professor Yanfeng Gao’s team from the School of Pharmaceutical Sciences (Shenzhen), Sun Yat-sen University have designed and synthesized Pal-DMPOP, a chimeric peptide that can simultaneously block CD47/SIRPα and PD-1/PD-L1. This bispecific peptide elicits synergistic antitumor activity by enhancing macrophages phagocytosis and activating CD8+ T cells. The findings are published in the journal Science China Life Sciences.